Quick Answer
RELMADA THERAPEUTICS, INC. reported Operating Income Loss of -$59.10 million for the year ending 2025.
- RELMADA THERAPEUTICS, INC. showed an increase of +29.6% in Operating Income Loss from 2024 to 2025.
- This data is from RELMADA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2012 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 15 years of available data (2012 to 2025), RELMADA THERAPEUTICS, INC.'s Operating Income Loss has declined by 490,276.7%.
- Historical annual values: Fiscal year 2025: -$59.10 million | Fiscal year 2024: -$83.89 million | Fiscal year 2023: -$103.70 million | Fiscal year 2022: -$161.25 million | Fiscal year 2021: -$125.70 million | Fiscal year 2020: -$60.84 million | Fiscal year 2019: -$15.11 million | Fiscal year 2019: -$12.73 million | Fiscal year 2018: -$6.92 million | Fiscal year 2017: -$7.22 million | Fiscal year 2016: -$16.22 million | Fiscal year 2015: -$17.10 million | Fiscal year 2013: -$6.77 million | Fiscal year 2013: -$45.0 thousand | Fiscal year 2012: -$12.1 thousand.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: